

# CITATION REPORT

List of articles citing

**Etanercept biosimilar SB-4**

**DOI: 10.1080/14712598.2019.1566456**

**Expert Opinion on Biological Therapy, 2019, 19, 173-179.**

**Source:** <https://exaly.com/paper-pdf/74684610/citation-report.pdf>

**Version:** 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	15
20	Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort. <i>Biologicals</i> , <b>2019</b> , 62, 27-32	1.8	6
19	Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , <b>2019</b> , 15, 1073-1079	2.9	11
18	Golimumab for Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	17
17	Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2153-2160	4	2
16	QL0902, a proposed etanercept biosimilar: pharmacokinetic and immunogenicity profile to its reference product in healthy Chinese male subjects. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 105-110	5.1	11
15	Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Discovery</i> , <b>2021</b> , 16, 227-234	6.2	2
14	LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 1-8	5.4	
13	Biologic Therapies and Autoimmune Phenomena. <i>Mediterranean Journal of Rheumatology</i> , <b>2021</b> , 32, 96-103	10.3	2
12	Cutaneous Autoimmune Phenomena of the Anti-TNF $\alpha$ Biosimilars. Casebased Review. <i>Current Rheumatology Reviews</i> , <b>2021</b> , 17, 267-270	1.6	2
11	The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. <i>Pharmaceutics</i> , <b>2020</b> , 13,	6.4	13
10	Tumor necrosis factor inhibitors as therapeutic agents for recurrent spontaneous abortion (Review). <i>Molecular Medicine Reports</i> , <b>2021</b> , 24,	2.9	2
9	Rheumatoid arthritis: Treatment evolution over the years. <b>2020</b> , 5, 024-026		1
8	Diagnostic Challenges and Management Update in Rheumatoid Arthritis.		
7	An etanercept O-glycovariant with enhanced potency.. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2022</b> , 25, 124-135	6.4	1
6	Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.. <i>Expert Review of Clinical Immunology</i> , <b>2022</b> , 1-9	5.1	0
5	Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs). <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X2210902	3.8	2

4	Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts. <i>European Respiratory Journal</i> , 2102307	13.6	o
3	Hadh deficiency induced oligoasthenoteratozoospermia through the TNF - <del>γ</del> Bcl-2 pathway in male mice. <b>2022</b> , 36,		o
2	Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data.		o
1	An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis. <b>2023</b> , 15, 1759720X2311586		o